| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
| US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
| US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(2 months from now) | |
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(4 months from now) | |
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(3 years ago) | |
| US7176211 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(2 months from now) | |
| US11344551 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US11707464 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US10537572 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
| US10682351 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
| US11690854 | ABBVIE | Methods of treating heavy menstrual bleeding |
Apr, 2038
(13 years from now) | |
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) | |
Orilissa is owned by Abbvie.
Orilissa contains Elagolix Sodium.
Orilissa has a total of 13 drug patents out of which 3 drug patents have expired.
Expired drug patents of Orilissa are:
- US7179815
- US6872728
- US7462625
Orilissa was authorised for market use on 23 July, 2018.
Orilissa is available in tablet;oral dosage forms.
Orilissa can be used as use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis, management of moderate to severe pain associated with endometriosis using 150 mg or 200 mg elagolix while co-administering omeprazole, management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin, management of moderate to severe pain associated with endometriosis in a patient with moderate hepatic impairment, management of moderate to severe pain associated with endometriosis, management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole, management of moderate to severe pain associated with endometriosis using 150 mg elagolix for up to 24 months.
Drug patent challenges can be filed against Orilissa from 23 July, 2022.
The generics of Orilissa are possible to be released after 27 August, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women havi...
Dosage: TABLET;ORAL
ORILISSA family patents
